{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:34:39Z","timestamp":1790883279768,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:00:00Z","timestamp":1712448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T00:00:00Z","timestamp":1712448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s40256-024-00638-4","type":"journal-article","created":{"date-parts":[[2024,4,7]],"date-time":"2024-04-07T08:01:36Z","timestamp":1712476896000},"page":"433-444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Trends in Oral Anticoagulant Use and Individual Expenditures Across the United States from 2014 to 2020"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7714-2945","authenticated-orcid":false,"given":"Omar S.","family":"Alkhezi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo F.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Fanikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,7]]},"reference":[{"key":"638_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.684638","author":"R Roberti","year":"2021","unstructured":"Roberti R, Iannone LF, Palleria C, et al. Direct oral anticoagulants: from randomized clinical trials to real-world clinical practice. Front Pharmacol. 2021. https:\/\/doi.org\/10.3389\/fphar.2021.684638. (Epub 26 May 2021).","journal-title":"Front Pharmacol"},{"key":"638_CR2","unstructured":"Pradaxa [package insert]. Ridgefield: Boehringer Ingelheim Pharmaceuticals, Inc.; 2023."},{"key":"638_CR3","unstructured":"Xarelto [package insert]. Titusville: Janssen Pharmaceuticals, Inc.; 2023."},{"key":"638_CR4","unstructured":"Eliquis [package insert]. Princeton: Bristol-Myers Squibb Company; 2021."},{"key":"638_CR5","unstructured":"Savaysa [package insert]. Basking Ridge: Daiichi Sankyo, Inc.; 2023."},{"issue":"14","key":"638_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319\u201330. https:\/\/doi.org\/10.1056\/NEJMoa1709118.","journal-title":"N Engl J Med"},{"issue":"21","key":"638_CR7","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","volume":"382","author":"MP Bonaca","year":"2020","unstructured":"Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994\u20132004. https:\/\/doi.org\/10.1056\/NEJMoa2000052.","journal-title":"N Engl J Med"},{"issue":"25","key":"638_CR8","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","volume":"375","author":"CM Gibson","year":"2016","unstructured":"Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1611594.","journal-title":"N Engl J Med"},{"issue":"16","key":"638_CR9","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1708454.","journal-title":"N Engl J Med"},{"issue":"16","key":"638_CR10","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","volume":"380","author":"RD Lopes","year":"2019","unstructured":"Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380(16):1509\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1817083.","journal-title":"N Engl J Med"},{"issue":"10206","key":"638_CR11","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","volume":"394","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(19)31872-0.","journal-title":"Lancet"},{"issue":"17","key":"638_CR12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","volume":"376","author":"H Calkins","year":"2017","unstructured":"Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation. N Engl J Med. 2017;376(17):1627\u201336. https:\/\/doi.org\/10.1056\/NEJMoa1701005.","journal-title":"N Engl J Med"},{"issue":"8","key":"638_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1814468.","journal-title":"N Engl J Med"},{"issue":"17","key":"638_CR14","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","volume":"382","author":"G Agnelli","year":"2020","unstructured":"Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020;382(17):1599\u2013607. https:\/\/doi.org\/10.1056\/NEJMoa1915103.","journal-title":"N Engl J Med"},{"issue":"23","key":"638_CR15","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","volume":"385","author":"NM Van Mieghem","year":"2021","unstructured":"Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385(23):2150\u201360. https:\/\/doi.org\/10.1056\/NEJMoa2111016.","journal-title":"N Engl J Med"},{"issue":"11","key":"638_CR16","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1056\/NEJMoa2209051","volume":"387","author":"SJ Connolly","year":"2022","unstructured":"Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J Med. 2022;387(11):978\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2209051.","journal-title":"N Engl J Med"},{"issue":"2","key":"638_CR17","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa1911425","volume":"382","author":"GD Dangas","year":"2020","unstructured":"Dangas GD, Tijssen JGP, W\u00f6hrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic-valve replacement. N Engl J Med. 2020;382(2):120\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1911425.","journal-title":"N Engl J Med"},{"issue":"20","key":"638_CR18","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1056\/NEJMoa1813959","volume":"380","author":"HC Diener","year":"2019","unstructured":"Diener HC, Sacco RL, Easton JD, et al. Dabigatran for prevention of stroke after embolic stroke of undetermined source. N Engl J Med. 2019;380(20):1906\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1813959.","journal-title":"N Engl J Med"},{"issue":"23","key":"638_CR19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1056\/NEJMoa1802686","volume":"378","author":"RG Hart","year":"2018","unstructured":"Hart RG, Sharma M, Mundl H, et al. Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med. 2018;378(23):2191\u2013201. https:\/\/doi.org\/10.1056\/NEJMoa1802686.","journal-title":"N Engl J Med"},{"issue":"14","key":"638_CR20","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","volume":"379","author":"F Zannad","year":"2018","unstructured":"Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med. 2018;379(14):1332\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1808848.","journal-title":"N Engl J Med"},{"issue":"10137","key":"638_CR21","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1016\/S0140-6736(18)30832-8","volume":"391","author":"PJ Devereaux","year":"2018","unstructured":"Devereaux PJ, Duceppe E, Guyatt G, et al. Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. Lancet. 2018;391(10137):2325\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(18)30832-8.","journal-title":"Lancet"},{"issue":"6","key":"638_CR22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1502000","volume":"373","author":"CV Pollack","year":"2015","unstructured":"Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373(6):511\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1502000.","journal-title":"N Engl J Med"},{"issue":"5","key":"638_CR23","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1056\/NEJMoa1707278","volume":"377","author":"CV Pollack","year":"2017","unstructured":"Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal\u2014full cohort analysis. N Engl J Med. 2017;377(5):431\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1707278.","journal-title":"N Engl J Med"},{"issue":"12","key":"638_CR24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","volume":"375","author":"SJ Connolly","year":"2016","unstructured":"Connolly SJ, Milling TJ, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131\u201341. https:\/\/doi.org\/10.1056\/NEJMoa1607887.","journal-title":"N Engl J Med"},{"issue":"25","key":"638_CR25","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","volume":"373","author":"DM Siegal","year":"2015","unstructured":"Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373(25):2413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1510991.","journal-title":"N Engl J Med"},{"key":"638_CR26","unstructured":"Wong SL, Marshall LZ, Lawson KA. Direct oral anticoagulant prescription trends, switching patterns, and adherence in Texas medicaid. Am J Manag Care. 2018;24(8):SP309-SP314."},{"issue":"6","key":"638_CR27","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1161\/STROKEAHA.118.023959","volume":"50","author":"NB Sur","year":"2019","unstructured":"Sur NB, Wang K, Di Tullio MR, et al. Disparities and temporal trends in the use of anticoagulation in patients with ischemic stroke and atrial fibrillation. Stroke. 2019;50(6):1452\u20139. https:\/\/doi.org\/10.1161\/STROKEAHA.118.023959.","journal-title":"Stroke"},{"issue":"4","key":"638_CR28","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1002\/rth2.12222","volume":"3","author":"PL Lutsey","year":"2019","unstructured":"Lutsey PL, Walker RF, MacLehose RF, Alonso A, Adam TJ, Zakai NA. Direct oral anticoagulants and warfarin for venous thromboembolism treatment: trends from 2012 to 2017. Res Pract Thromb Haemost. 2019;3(4):668\u201373. https:\/\/doi.org\/10.1002\/rth2.12222.","journal-title":"Res Pract Thromb Haemost."},{"issue":"16","key":"638_CR29","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2146\/ajhp160756","volume":"74","author":"AA Alalwan","year":"2017","unstructured":"Alalwan AA, Voils SA, Hartzema AG. Trends in utilization of warfarin and direct oral anticoagulants in older adult patients with atrial fibrillation. Am J Health Syst Pharm. 2017;74(16):1237\u201344. https:\/\/doi.org\/10.2146\/ajhp160756.","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"638_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.amjmed.2018.09.026","volume":"132","author":"BA Rodwin","year":"2019","unstructured":"Rodwin BA, Salami JA, Spatz ES, et al. Variation in the use of warfarin and direct oral anticoagulants in atrial fibrillation and associated cost implications. Am J Med. 2019;132(1):61-70.e1. https:\/\/doi.org\/10.1016\/j.amjmed.2018.09.026.","journal-title":"Am J Med"},{"key":"638_CR31","unstructured":"NHIS\u2014National Health Interview Survey. Centers for disease control and prevention. https:\/\/www.cdc.gov\/nchs\/nhis\/index.htm. Accessed 8 Dec 2022."},{"key":"638_CR32","unstructured":"Chowdhury SR, Machlin SR GK. Sample designs of the medical expenditure panel survey household component, 1996\u20132006 and 2007\u20132016. Methodology Report #33. Rockville: Agency for Healthcare Research and Quality"},{"key":"638_CR33","unstructured":"Hill SC, Roemer M SM. Outpatient prescription drugs: data collection and editing in the 2011 medical expenditure panel survey. Methodology Report #29. Rockville: Agency for Healthcare Research and Quality."},{"issue":"3","key":"638_CR34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2307\/1402588","volume":"51","author":"DA Binder","year":"1983","unstructured":"Binder DA. On the variances of asymptotically normal estimators from complex surveys. Int Stat Rev Rev Int Stat. 1983;51(3):279. https:\/\/doi.org\/10.2307\/1402588.","journal-title":"Int Stat Rev Rev Int Stat."},{"issue":"4","key":"638_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.14503\/THIJ-16-5785","volume":"43","author":"RM Wehbe","year":"2016","unstructured":"Wehbe RM, Yadlapati A. Underuse of oral anticoagulants for nonvalvular atrial fibrillation: past, present, and future. Texas Hear Inst J. 2016;43(4):287\u201390. https:\/\/doi.org\/10.14503\/THIJ-16-5785.","journal-title":"Texas Hear Inst J."},{"issue":"3","key":"638_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40256-016-0161-8","volume":"16","author":"EA Alamneh","year":"2016","unstructured":"Alamneh EA, Chalmers L, Bereznicki LR. Suboptimal use of oral anticoagulants in atrial fibrillation: Has the introduction of direct oral anticoagulants improved prescribing practices? Am J Cardiovasc Drugs. 2016;16(3):183\u2013200. https:\/\/doi.org\/10.1007\/s40256-016-0161-8.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"638_CR37","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1001\/jamacardio.2015.0374","volume":"1","author":"JC Hsu","year":"2016","unstructured":"Hsu JC, Maddox TM, Kennedy KF, et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE Registry. JAMA Cardiol. 2016;1(1):55\u201362. https:\/\/doi.org\/10.1001\/jamacardio.2015.0374.","journal-title":"JAMA Cardiol."},{"issue":"25","key":"638_CR38","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1016\/j.jacc.2016.03.581","volume":"67","author":"JC Hsu","year":"2016","unstructured":"Hsu JC, Maddox TM, Kennedy K, et al. Aspirin instead of oral anticoagulant prescription in atrial fibrillation patients at risk for stroke. J Am Coll Cardiol. 2016;67(25):2913\u201323. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.581.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"638_CR39","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1177\/1074248419841634","volume":"24","author":"AJ Kattoor","year":"2019","unstructured":"Kattoor AJ, Pothineni NV, Goel A, et al. Prescription patterns and outcomes of patients with atrial fibrillation treated with direct oral anticoagulants and warfarin: a real-world analysis. J Cardiovasc Pharmacol Ther. 2019;24(5):428\u201334. https:\/\/doi.org\/10.1177\/1074248419841634.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"638_CR40","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11886-021-01456-9","volume":"23","author":"EM White","year":"2021","unstructured":"White EM, Coons JC. Direct oral anticoagulant use in special populations: elderly, obesity, and renal failure. Curr Cardiol Rep. 2021;23(4):27. https:\/\/doi.org\/10.1007\/s11886-021-01456-9.","journal-title":"Curr Cardiol Rep"},{"issue":"2","key":"638_CR41","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s11239-020-02179-4","volume":"51","author":"MN Elshafei","year":"2021","unstructured":"Elshafei MN, Mohamed MFH, El-Bardissy A, et al. Comparative effectiveness and safety of direct oral anticoagulants compared to warfarin in morbidly obese patients with acute venous thromboembolism: systematic review and a meta-analysis. J Thromb Thrombol. 2021;51(2):388\u201396. https:\/\/doi.org\/10.1007\/s11239-020-02179-4.","journal-title":"J Thromb Thrombol"},{"issue":"4","key":"638_CR42","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1136\/bmjebm-2020-111634","volume":"27","author":"R Noviyani","year":"2022","unstructured":"Noviyani R, Youngkong S, Nathisuwan S, et al. Economic evaluation of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKAs) for stroke prevention in patients with atrial fibrillation: a systematic review and meta-analysis. BMJ Evid Based Med. 2022;27(4):215\u201323. https:\/\/doi.org\/10.1136\/bmjebm-2020-111634.","journal-title":"BMJ Evid Based Med."},{"key":"638_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.675200","author":"Y Wu","year":"2021","unstructured":"Wu Y, Zhang C, Gu ZC. Cost-effectiveness analysis of direct oral anticoagulants Vs. Vitamin K antagonists in the elderly with atrial fibrillation: insights from the evidence in a real-world setting. Front Cardiovasc Med. 2021. https:\/\/doi.org\/10.3389\/fcvm.2021.675200.","journal-title":"Front Cardiovasc Med."},{"key":"638_CR44","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.jval.2018.04.367","volume":"21","author":"Y Huang","year":"2018","unstructured":"Huang Y, Chen S, Wang Y, Zhao B. Cost effectiveness of direct oral anticoagulants (DOACS) compared with warfarin: a literature review. Value Heal. 2018;21:S60. https:\/\/doi.org\/10.1016\/j.jval.2018.04.367.","journal-title":"Value Heal."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00638-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40256-024-00638-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-024-00638-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T07:12:58Z","timestamp":1715670778000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40256-024-00638-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,7]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["638"],"URL":"https:\/\/doi.org\/10.1007\/s40256-024-00638-4","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,7]]},"assertion":[{"value":"10 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors did not receive support from any organizations for the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Omar S. Alkhezi, Leo F. Buckley, and John Fanikos have no conflicts of interest to declare relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Data used in this study can be found at","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Omar S. Alkhezi, Leo F. Buckley and John Fanikos. The first draft of the manuscript was written by Omar S. Alkhezi and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}